New cream could soothe stubborn hand eczema in teens

NCT ID NCT05355818

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a cream called delgocitinib in 98 teens aged 12-17 with moderate to severe chronic hand eczema. Participants applied the cream or a placebo twice daily for 16 weeks. Doctors checked how well the cream cleared eczema and tracked side effects. The goal is to see if this cream offers a new option for teens who haven't gotten relief from standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delgocitinib cream
What this could lead to: If successful, this could provide a new treatment option for teens with chronic hand eczema that hasn't responded well to standard steroid creams.
What could go wrong: This is a Phase 3 trial, but results are not yet published. The cream may not work better than the placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HAND ECZEMA

Contacts and locations

Locations

LEO Pharma investigational site

Darlinghurst, 2010, Australia
LEO Pharma investigational site

Mitcham, 3132, Australia
LEO Pharma investigational site

Phillip, 2606, Australia
LEO Pharma investigational site

Woolloongabba, 4102, Australia
LEO Pharma investigational site

Brussels, 1200, Belgium
LEO Pharma investigational site

Ghent, 9000, Belgium
LEO Pharma investigational site

Gilly, 6060, Belgium
LEO Pharma investigational site

Liège, 4000, Belgium
LEO Pharma investigational site

Edmonton, T6G 1C3, Canada
LEO Pharma investigational site

Fredericton, E3B 1G9, Canada
LEO Pharma investigational site

Kingston, K7L 2V7, Canada
LEO Pharma investigational site

Montreal, H3T 1C5, Canada
LEO Pharma investigational site

Red Deer, T4P1K4, Canada
LEO Pharma investigational site

St. John's, NL A1E 1V4, Canada
LEO Pharma investigational site

Toronto, M2N 3A6, Canada
LEO Pharma investigational site

Winnipeg, R3C 0N2, Canada
LEO Pharma investigational site

Martigues, Bouches-du-Rhône, 13500, France
LEO Pharma investigational site

Nice, 06000, France
LEO Pharma investigational site

Reims, 51100, France
LEO Pharma investigational site

Toulouse, 31059, France
LEO Pharma investigational site

Chorzów, 41-516, Poland
LEO Pharma investigational site

Krakow, 30-002, Poland
LEO Pharma investigational site

Krakow, 30-033, Poland
LEO Pharma investigational site

Krakow, 31-011, Poland
LEO Pharma investigational site

Warsaw, 02-625, Poland
LEO Pharma investigational site

Wroclaw, 51-503, Poland
LEO Pharma investigational site

Alicante, 03010, Spain
LEO Pharma investigational site

Barcelona, 08041, Spain
LEO Pharma investigational site

Cadiz, 11009, Spain
LEO Pharma investigational site

Esplugues de Llobregat, 08950, Spain
LEO Pharma investigational site

Fuenlabrada, 28942, Spain
LEO Pharma investigational site

Granada, 18016, Spain
LEO Pharma investigational site

Ipswich, IP4 5PD, United Kingdom
LEO Pharma investigational site

Kings Lynn, PE30 4ET, United Kingdom
LEO Pharma investigational site

Lincoln, LN2 5QY, United Kingdom
LEO Pharma investigational site

London, SW10 9NH, United Kingdom
LEO Pharma investigational site

Walsall, WS2 9PS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.